News | Thrombectomy Devices | November 12, 2021

New Data Demonstrate Safety and Performance of Continuous Aspiration Thrombectomy With Penumbra’s Indigo System CAT RX Catheter

CHEETAH clinical study showed CAT RX established high rates of blood clot removal, blood flow restoration and myocardial perfusion normalization

Penumbra Indigo System CAT RX Thrombectomy system was involved in the CHEETAH Trial, study at TCT 2021.#TNT

November 12, 2021 — Penumbra Inc. announced that the CHEETAH clinical study of its Indigo System CAT RX Catheter successfully met the primary endpoint and demonstrated high rates of blood clot removal, blood flow restoration and myocardial perfusion in conjunction with percutaneous coronary intervention (PCI) in patients with high thrombus burden. The results were presented at the 2021 Transcatheter Cardiovascular Therapeutics (TCT) conference in Orlando.

“These results are very promising as they demonstrate the significant benefits and safety of continuous powered aspiration thrombectomy for those patients with high thrombus burden, which can often be life-threatening,” said National Principal Investigator S. Jay Mathews, M.D., M.S., director, cardiac catheterization laboratory, Manatee Memorial Hospital in Bradenton, Fla. “After only one pass with Penumbra’s CAT RX, we were pleased to see restoration of blood flow and perfusion when used upfront in acute coronary syndrome interventions.”

The CHEETAH clinical study enrolled 400 patients with high thrombus burden who were treated with continuous mechanical aspiration thrombectomy with CAT RX prior to PCI. Notable findings include:

Significant reduction in Thrombolysis in Myocardial Infarction (TIMI) thrombus grade: 99.5% of patients achieved TIMI thrombus grade 0 after CAT RX and PCI.

Improved TIMI flow grade: 97.5% of patients TIMI flow grade 3 after CAT RX and PCI. TIMI 2-3 increased significantly from 16.6% at baseline to 85% after CAT RX alone.

Enhanced myocardial blush grade (MBG): 99.8% of patients achieved MBG 3 after CAT RX and PCI.

No device-related serious adverse events occurred.

As part of the Indigo Aspiration System, the Indigo CAT RX Aspiration Catheters and Indigo Separator 4 are indicated for the removal of fresh, soft emboli and thrombi from vessels in the coronary and peripheral vasculature. 

“This is the first large study to demonstrate the significant benefits of continuous aspiration,” said Sahil Parikh, M.D., associate professor of medicine at Columbia University Irving Medical Center in New York. “Such immediate and robust reperfusion with CAT RX is encouraging as physicians are in a race against time to safely restore blood flow in heart attack patients. The CHEETAH study suggests that CAT RX power aspiration is both safe and effective in a high-risk coronary patient population. This data highlights the importance of innovation in technology and hopefully will lead to further improvements in meaningful clinical outcomes for our patients.”

In the study, the CAT RX procedure took about 69 seconds to complete. It enhanced visualization of target lesions by approximately 95% and had low rates of distal embolization.  

“The CHEETAH study highlights the safety and performance of CAT RX for removing blood clots in the coronary arteries and restoring blood flow in a short period of time,” said James F. Benenati, M.D., FSIR, chief medical officer at Penumbra. “The findings suggest that continuous aspiration should be a key consideration given that removing the blood clots improves perfusion to the heart and also allows for more precise visualization of coronary lesions potentially leading to improving patient outcomes.” 

About the CHEETAH Study

The CHEETAH study, a prospective, single-arm, multicenter study of continuous mechanical aspiration thrombectomy with CAT RX prior to PCI, evaluated 400 patients at 25 centers in the U.S. Adults presenting within 12 hours of symptom onset, with target lesions located in a native coronary artery and high thrombus burden were eligible for enrollment. The primary endpoint was a composite MACE of cardiovascular death, recurrent myocardial infarction, cardiogenic shock or new or worsening NYHA Class IV heart failure within 30 days. Key secondary endpoints included Core Lab adjudicated final TIMI flow and thrombus grade, MBG, distal embolization rate, incidence of device related serious adverse events (SAEs) and stroke within 30 days. All safety events were independently adjudicated.

For more information: www.penumbrainc.com

Find more TCT news 


Related Content

Videos | TCT

At TCT 2022, Jane Leopold, MD, a cardiologist at Brigham and Women’s Hospital; Director, Women's Interventional ...

Home November 03, 2022
Home
Videos | TCT

At TCT 2022, Jane Leopold, MD, a cardiologist at Brigham and Women’s Hospital; Director, Women's Interventional ...

Home October 26, 2022
Home
Feature | TCT | Christine Book

October 17, 2022 — Significant findings from the highly-anticipated EPIC-STEMI study were presented during a late ...

Home October 17, 2022
Home
Videos | TCT

At TCT 2022, Deepak Bhatt, MD, MPh, Executive Director of Interventional Cardiovascular Programs, Brigham and Women's ...

Home October 13, 2022
Home
Feature | TCT | By Christine Book

The 34th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research ...

Home October 03, 2022
Home
News | TCT

September 22, 2022 — The recipient of the TCT 2022 Thomas J. Linnemeier “Spirit of Interventional Cardiology” Young ...

Home September 22, 2022
Home
News | TCT

September 19, 2022 — Puzzle Medical Devices, a provider of hemodynamic support in Heart Failure (HF), was selected as ...

Home September 20, 2022
Home
News | TCT

September 16, 2022 — Edwards Lifesciences Corporation, today announced the company's PASCAL Precision transcatheter ...

Home September 16, 2022
Home
News | TCT

September 16, 2022 — CathWorks announced today the schedule of key events for the company during Cardiovascular Research ...

Home September 16, 2022
Home
Subscribe Now